

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study

Authors: Ana Florea, PhD¹, Lina S. Sy, MPH¹, Yi Luo, PhD¹, Lei Qian, PhD¹, Katia J. Bruxvoort, PhD^{1,2}, Bradley K. Ackerson, MD¹, Gina S. Lee, MPH¹, Jennifer H. Ku, PhD¹, Julia E. Tubert, MPH¹, Yun Tian, MS¹, Carla A. Talarico³, Hung Fu Tseng, PhD^{1,4}

Affiliations: ¹Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA; ²Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL 35233, USA; ³Moderna Inc., 200 Technology Square, Cambridge, MA, 02139, USA; ⁴Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA 91101, USA

Corresponding Author:

Ana Florea, PhD, MPH
Department of Research & Evaluation
Kaiser Permanente Southern California
100 S Los Robles, Pasadena, CA 91101
Email: ana.florea@kp.org
ORCID ID: 0000-0003-0030-8737

Alternate Corresponding Author:

Lina S. Sy, MPH
Department of Research & Evaluation
Kaiser Permanente Southern California
100 S Los Robles, Pasadena, CA 91101
Email: lina.s.sy@kp.org

Keywords: COVID-19; SARS-CoV-2; mRNA-1273; vaccine effectiveness; Delta variant

Running Title: mRNA-1273 effectiveness during Delta

Summary

This prospective cohort study provides evidence for continued protection of 2 doses of mRNA-1273 against SARS-CoV-2 infection over 8 months post-vaccination and during the Delta period. VE against COVID-19 hospitalization remained robust and stable over the same period.

Abstract

Background: We conducted a prospective cohort study at Kaiser Permanente Southern California to study the vaccine effectiveness (VE) of mRNA-1273 over time and during the emergence of the Delta variant.

Methods: The cohort for this planned interim analysis consisted of individuals aged ≥ 18 years receiving 2 doses of mRNA-1273 through June 2021, matched 1:1 to randomly selected unvaccinated individuals by age, sex, and race/ethnicity, with follow-up through September 2021. Outcomes were SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHR) with 95% confidence intervals (CIs) comparing outcomes in the vaccinated and unvaccinated groups. Adjusted VE (%) was calculated as $(1 - \text{aHR}) \times 100$. HRs and VEs were also estimated for SARS-CoV-2 infection by age, sex, race/ethnicity, and during the Delta period (June-September 2021). VE against SARS-CoV-2 infection and COVID-19 hospitalization was estimated at 0- <2 , 2- <4 , 4- <6 , and 6- <8 months post-vaccination.

Results: 927,004 recipients of 2 doses of mRNA-1273 were matched to 927,004 unvaccinated individuals. VE (95% CI) was 82.8% (82.2-83.3%) against SARS-CoV-2 infection, 96.1% (95.5-96.6%) against COVID-19 hospitalization, and 97.2% (94.8-98.4%) against COVID-19 hospital death. VE against SARS-CoV-2 infection was similar by age, sex, and race/ethnicity, and was 86.5% (84.8-88.0%) during the Delta period. VE against SARS-CoV-2 infection decreased from 88.0% at 0- <2 months to 75.5% at 6- <8 months.

Conclusions: These interim results provide continued evidence for protection of 2 doses of mRNA-1273 against SARS-CoV-2 infection over 8 months post-vaccination and during the Delta period, and against COVID-19 hospitalization and hospital death.

Introduction

Since coronavirus disease 2019 (COVID-19) vaccine rollout, multiple observational studies have demonstrated that mRNA-1273 (Moderna Inc, Cambridge, USA) is highly effective against symptomatic COVID-19, with reports of vaccine effectiveness (VE) as high as 100% [1-4]. mRNA-1273 has also been shown to have high VE against COVID-19 hospitalization and death [1, 3].

However, the emergence of several SARS-CoV-2 variants led to concerns of potentially lower VE of COVID-19 vaccines against variants [5, 6]. The higher transmissibility of the Delta variant led to a surge in infections, hospitalizations, and deaths in the United States (US) since becoming the dominant circulating strain in July 2021 [7, 8]. Even though a majority of cases were in unvaccinated individuals, breakthrough cases among vaccinated individuals have also been reported [9-12]. We previously evaluated the VE of mRNA-1273 against SARS-CoV-2 variants, and reported an overall VE of 86.7% against Delta infection through July 2021 [13]. Another test-negative observational study in Ontario, Canada, from December 2020 to August 2021, reported a 94% VE against symptomatic infection with Delta after two doses of mRNA-1273 with similar VE against hospitalization and death [14]. Furthermore, several studies conducted in the US post Delta emergence reported high VE of mRNA-1273 against COVID-19 hospitalization ranging from 91.6% to 95.0% [15-17].

As the pandemic continues, the durability of protection of COVID-19 vaccines, for which data are limited [18], and the potential need for boosters have become critical public health questions. We previously reported that waning of VE was most pronounced for the Delta variant, with VE against Delta infection declining from 94.1% at 14-60 days after vaccination to 80.0% at 151-180 days after vaccination [13]. A test-negative study conducted in the United Kingdom compared VE of mRNA-1273 against Delta symptomatic disease over 14 weeks, showing a decline in VE from 95.2% at 1 week after vaccination to 90.3% at 14 weeks after vaccination [19].

Few published studies are available on the durability of protection of mRNA-1273 several months after vaccination during the Delta period among the general US population. In this study, we evaluated the durability (with up to 8 months of follow-up) and effectiveness of 2 doses of mRNA-

1273 in preventing SARS-CoV-2 infection, stratified by age, sex, and race/ethnicity, and during the Delta period in the US. We also evaluated VE and durability against COVID-19 hospitalization.

Methods

Study setting

Kaiser Permanente Southern California (KPSC) is an integrated health care system providing care to a diverse 4.6 million members[20]. KPSC's electronic health record (EHR) is comprehensive, capturing details across several areas such as inpatient, outpatient, emergency, and virtual care; claims also capture any care received outside of the KPSC system. The KPSC Institutional Review Board reviewed and approved the study.

Study objectives

This is the second planned interim analysis (IA) of a 5-year cohort study at KPSC to evaluate the VE of mRNA-1273 in preventing SARS-CoV-2 infection and severe COVID-19 disease. Detailed methods and results of the first IA with follow-up through June 30, 2021 were reported elsewhere [1]. For this analysis, the primary objectives were to evaluate the VE of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection and severe COVID-19 disease. Secondary objectives were to evaluate the VE of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection by age, sex, and race/ethnicity groups. We also evaluated the waning of VE over time to assess the durability of mRNA-1273 against SARS-CoV-2 infection and COVID-19 hospitalization. To specifically assess VE against Delta in the absence of waning, we also evaluated VE against Delta infection in individuals newly vaccinated in June 2021 and followed through September 30, 2021. The study protocol is presented in the Supplementary Materials.

Study population

For the study cohort, eligible individuals were ≥ 18 years old, and were KPSC members for at least 1 year prior to the index date (allowing a 31-day membership gap) and for ≥ 14 days after the index date. Individuals who received 2 doses of mRNA-1273 ≥ 24 days apart (4-day grace period allowed prior to the recommended 28-day interval) from December 18, 2020 through June 30, 2021 made up the vaccinated group. The index date was defined as the date of receipt of the second dose of mRNA-1273 for vaccinated individuals; their matched unvaccinated counterparts were assigned the same

index date. Individuals who received a COVID-19 vaccine other than mRNA-1273 on or before the index date, or who had no healthcare utilization or no vaccination from the 2 years prior to the index date through the index date were excluded. Individuals who died, had a COVID-19 outcome, or received any COVID-19 vaccine \leq 14 days after the index date were also excluded.

The unvaccinated group was composed of those who did not receive any COVID-19 vaccine as of the index date. Unvaccinated comparators were randomly selected and matched 1:1 to the vaccinated individuals by age group (18–44 years, 45–64 years, 65–74 years, and \geq 75 years), sex, and race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Non-Hispanic Asian, and Other/Unknown). Index dates were also balanced through matching, since matched vaccinated and unvaccinated individuals shared the same index date.

Exposure and outcomes

Information on mRNA-1273 exposure was ascertained from KPSC's EHR. The EHR included vaccines administered within KPSC as well as COVID-19 vaccines administered outside of the KPSC health system. These were imported daily into the KPSC EHR from the California Immunization Registry (CAIR), CalVax (Cal Poly Pomona mass vaccination site), Care Everywhere (Epic EHR feature which allows health care systems to exchange medical information), claims (e.g., pharmacies), and member self-report with documentation. All providers of COVID-19 vaccines were required by law to provide COVID-19 vaccine administration data daily to CAIR [21].

The first primary outcome was SARS-CoV-2 infection defined as a positive molecular test or a COVID-19 diagnosis code for both symptomatic and asymptomatic infections. Individuals with COVID-19 who had a history of a COVID-19 diagnosis code or a SARS-CoV-2 positive molecular test in the 90 days prior were not considered incident cases. The second primary outcome was severe COVID-19 disease, which included COVID-19 hospitalization (hospitalization with a SARS-CoV-2 positive test or a COVID-19 diagnosis code, or a hospitalization \leq 7 days after a SARS-CoV-2 positive test) and COVID-19 hospital death (death occurring during COVID-19 hospitalization). COVID-19 hospitalization was confirmed 1) by at least one documented SpO₂ <90% during hospital stay, or 2) if

SpO₂ ≥90%, by manual chart review done by a physician investigator [BKA] and trained chart abstractors to verify the presence of severe COVID-19 symptoms.

Individuals were followed for COVID-19 outcomes ≥14 days after the index date through September 30, 2021 (end of follow-up) or until occurrence of a censoring event (termination of KPSC membership allowing for a 31-day gap, death, or receipt of a COVID-19 vaccine), resulting in up to 8 months of follow-up post-vaccination for this analysis. Unvaccinated individuals stopped contributing unvaccinated person-time if they received a first dose of mRNA-1273 during follow-up and started contributing vaccinated person-time when they received an eligible second dose of mRNA-1273.

Starting from June 1, 2021, Delta (B.1.617.2, AY.*) was the predominant strain among positive SARS-CoV-2 specimens successfully sequenced at KPSC [1]. To evaluate VE of mRNA-1273 specifically against SARS-CoV-2 infection during the Delta period, a subset of individuals was included in an additional Delta period analysis if they had an index date during June 1-30, 2021 and were followed up to September 30, 2021.

Other variables

Baseline characteristics were extracted from the EHR. Variables assessed at index date included age, sex, race/ethnicity, socioeconomic status (Medicaid coverage, neighborhood median household income), medical center area, pregnancy status, and KPSC physician/employee status. Variables assessed in the two years prior to index date included smoking and body mass index (BMI). Variables assessed in the year prior to index date included Charlson comorbidity score, autoimmune conditions, health care utilization (virtual, outpatient, emergency department [ED], inpatient encounters), preventive care (other vaccinations, screenings, well-visits), chronic diseases (kidney disease, heart disease, lung disease, liver disease, diabetes), and frailty index [22]. Other variables included history of SARS-CoV-2 infection and molecular test performed from March 1, 2020 to index date (irrespective of result), and immunocompromised status.

Statistical analyses

Baseline characteristics of the vaccinated and unvaccinated groups were described. Continuous variables were compared using two-sample t-test or Wilcoxon rank-sum test, as appropriate, and categorical variables were compared using χ^2 test or Fisher's exact test, as appropriate. Potential confounders were identified based on the literature. To assess the balance of covariates across groups, absolute standardized differences (ASD) were used. Covariates with ASD>0.1, as well as age, sex, race/ethnicity, month of index date were included in the multivariable models. The missing indicator method was used for covariates with missing data [23].

The number of incident events divided by person-years was used to calculate the incidence rates (IR) per 1,000 person-years of SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death for both vaccinated and unvaccinated groups. Kaplan-Meier curves were used to estimate the cumulative incidence of SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death for both groups; the differences between the curves were tested by log-rank test.

Cox proportional hazards regression models were used to estimate unadjusted and adjusted hazard ratios (HR) with 95% confidence intervals (CIs) comparing SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death in the vaccinated and unvaccinated groups overall. VE (%) was calculated as $(1-\text{HR}) \times 100$. HRs and VEs were also estimated comparing SARS-CoV-2 infection in vaccinated and unvaccinated individuals by age, sex, race/ethnicity, and during the Delta period.

To evaluate durability of protection, VE against SARS-CoV-2 infection and COVID-19 hospitalization was estimated every two months post-vaccination (0-<2, 2-<4, 4-<6, and 6-<8 months) using time-varying Cox regression models. VEs by months post-vaccination against SARS-CoV-2 infection and COVID-19 hospitalization were also estimated and stratified by age groups (18-64 years old and ≥ 65 years old).

All analyses were conducted using SAS software version 9.4, Cary, USA.

Results

Baseline characteristics

The study cohort consisted of 927,004 recipients of 2 doses of mRNA-1273 vaccine (hereafter, 'vaccinated') and 927,004 matched unvaccinated individuals (**Figure 1**). Overall, the median age was 52 years (interquartile range [IQR] 36-65) with 74.3% aged 18-64 years; there were more females than males (54.5%); and 38.6% were Hispanic, 33.6% were non-Hispanic White, 12.8% were Asian, and 7.5% were Black (**Table 1**). The vaccinated and unvaccinated groups had similar characteristics (ASD \leq 0.1) of BMI, smoking, Charlson comorbidities index, frailty index, chronic diseases, immunocompromised status, autoimmune conditions, pregnancy status, history of SARS-CoV-2 infection and molecular test, ED visits, hospitalizations, Medicaid enrollment, and median household income. Compared to the unvaccinated individuals, those vaccinated had more outpatient and virtual visits, and more preventive care visits in the year prior to the index date. A higher proportion of vaccinated individuals were KPSC physicians/employees. There were some differences in the distribution of vaccinated and unvaccinated groups across the medical centers. The greatest proportion of index dates occurred in April 2021 (34.5%) followed by May 2021 (21.2%), coinciding with California's vaccination phase when mRNA-1273 became available to all individuals \geq 18 years old [24]. Vaccinated individuals received their second dose after a median 28 days (IQR 28-29) post-first dose, and 0.1% received a concomitant vaccine with mRNA-1273.

VE against SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death

There were 7,685 cases of SARS-CoV-2 infection among the vaccinated individuals and 16,809 cases among the unvaccinated individuals, with IRs per 1,000 person-years of 19.09 (95% CI: 18.67-19.52) and 94.02 (95% CI: 92.61-95.45), respectively (**Table 2**). IRs per 1,000 person-years for COVID-19 hospitalization and COVID-19 hospital death were 0.60 (95% CI: 0.53-0.69) and 0.03 (95% CI: 0.02-0.06), respectively, among vaccinated individuals and 13.07 (95% CI: 12.55-13.61) and 0.90 (95% CI: 0.77-1.05), respectively, among the unvaccinated individuals. The cumulative incidences of SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death were all significantly higher in unvaccinated individuals than vaccinated individuals (log-rank test $p < 0.001$) (**Figures 2a-c**). The adjusted VE (**Table 2**) was 82.8% (95% CI: 82.2-83.3%) against SARS-CoV-2 infection; 96.1% (95% CI: 95.5-96.6%) against COVID-19 hospitalization; and 97.2% (95% CI: 94.8-98.4%) against COVID-19 hospital death.

VE against SARS-CoV-2 infection by subgroups

Among vaccinated and unvaccinated groups, the IR of SARS-CoV-2 infection was higher in those <65 years as compared to those ≥65 years (**Table 3**). IRs among vaccinated and unvaccinated females were higher than their male counterparts. IRs were higher among Hispanic individuals in the vaccinated group (23.03 [95% CI: 22.28-23.81]) and among non-Hispanic Black individuals in the unvaccinated group (109.90 [95% CI: 104.47-115.61]) when compared to the other racial/ethnic groups. Despite differences in IRs of SARS-CoV-2 infection across age, sex, and race/ethnicity groups, the adjusted VE against SARS-CoV-2 infection was similar by age, sex, and race/ethnicity, ranging from 77.9% to 87.0%. Among the subgroup of individuals who completed their 2-dose series in June 2021 and their unvaccinated matched counterparts, the IRs for SARS-CoV-2 infection during the Delta period were 20.38 (95% CI: 18.27-22.75) and 146.73 (95% CI: 140.40-153.35), respectively (**Table 3**). Adjusted VE against SARS-CoV-2 infection comparing individuals vaccinated during the Delta period and their unvaccinated counterparts was 86.5% (95% CI: 84.8-88.0%).

Durability of protection

Adjusted VE against SARS-CoV-2 infection and COVID-19 hospitalization by months after vaccination both overall and by age groups are presented in **Supplementary Table 1**. Adjusted VE against SARS-CoV-2 infection decreased from 88.0% at 0-<2 months to 75.5% at 6-<8 months (**Figure 3**). Adjusted VE against COVID-19 hospitalization remained stable, from 95.9% in 0-<2 months to 94.5% in 6-<8 months. The durability of protection VE estimates by age groups for both SARS-CoV-2 infection and COVID-19 hospitalization were similar to the overall results.

Discussion

This interim analysis was conducted among a large cohort to assess the effectiveness and durability of 2 doses of mRNA-1273 under real-world conditions. The study results confirmed the high effectiveness of 2 doses of mRNA-1273, with VE against SARS-CoV-2 infection of 82.8%, VE against COVID-19 hospitalization of 96.1%, and VE against COVID-19 hospital death of 97.2%. Furthermore, VE against COVID-19 hospitalization remained robust and stable over 8 months of follow-up. Moderate waning was observed for VE against SARS-CoV-2 infection, with a VE of 75.5% at 6-<8 months post-vaccination. The individuals included in the cohort were vaccinated through June 2021

and then followed through September 2021, overlapping with the rapid spread of the Delta variant in the US. Additionally, for individuals who completed the two-dose series in June 2021, VE against SARS-CoV-2 infection during the Delta period remained high at 86.5% through the end of September 2021.

These results add to a growing body of work evaluating the VE of mRNA-1273 in the general population. A case-control study across 21 hospitals in 18 US states assessing the VE of mRNA-1273 in preventing COVID-19 hospitalizations during March 11, 2021 to August 15, 2021 reported a VE of 93% (95% CI: 91%-95%), similar to the VE found in this study [25]. The findings of our study are also consistent with and extend those of our prior interim analysis [1] with follow-up through June 2021. VE against COVID-19 hospitalization and hospital death was higher than the VE against SARS-CoV-2 infection, corroborating previous evidence that mRNA vaccines offer greater protection against more severe disease [1, 26, 27].

We previously found mRNA-1273 to have a high VE against SARS-CoV-2 infection before the Delta variant spread in the US [1]. The Delta variant started emerging in the US in late May 2021 and quickly became the dominant variant during June through August 2021 [28]. A study in Qatar evaluated VE of mRNA-1273 against the Delta variant [29], and found a VE against SARS-CoV-2 infection of 73.1% (95% CI: 67.5%-77.8%). In the current study, VE against SARS-CoV-2 infection was evaluated for the Delta period in a subset of individuals newly vaccinated during June 2021 and followed up through September 2021; VE against Delta after three months of follow-up was 86.5%, similar to the VE observed in our prior interim analysis (87.4%) [1]. This finding is less subject to waning and suggests that mRNA-1273 generates protection against the Delta variant.

The current study is also one of the first to examine the durability of the 2-dose mRNA-1273 vaccine. While VE against COVID-19 hospitalization was stable during the follow-up, VE against SARS-CoV-2 infection steadily decreased from 88.0% to 75.5% across the 8 months of follow-up. The same VE waning effects were apparent across age categories (18-64 years and ≥ 65 years). These findings are consistent with the findings of our previous study that used a test-negative design [13]. Due to this

steady decrease in VE, our findings support the current mRNA-1273 booster recommendations of receiving a booster shot at least 6 months after completing the primary series [30].

One strength of the current study is the matched cohort design which allows for generalizability to the general population eligible for mRNA-1273. Another strength is KPSC's diverse member population. The study also utilized KPSC's EHR and was able to gather comprehensive data on millions of members; the data included COVID-19 vaccine information, demographics, medical history, and health care utilization. However, residual confounding from unmeasured factors might have still been present. Some health seeking behaviors such as adherence to masking guidelines and occupation are not captured by the EHR; these may contribute to differences in COVID-19 risk and testing behaviors between vaccinated and unvaccinated individuals. Misclassification of SARS-CoV-2 infection from false positive or false negative test results or from inaccurate diagnosis codes from outside claims may have been another limitation. This non-differential misclassification could have underestimated the VE. Lastly, individuals vaccinated during the Delta period were younger as vaccines had recently become available to the general population and may have had fewer COVID-19 risk factors, which could have led to overestimation of VE during the Delta period.

In conclusion, this second interim analysis of an ongoing cohort study found that VE of 2 doses of mRNA-1273 against SARS-CoV-2 infection declined moderately over the course of 8 months, but VE against COVID-19 hospitalization remained robust and stable over the same period. In addition, VE against SARS-CoV-2 infection in newly vaccinated individuals during the Delta period remained high. Continued long-term follow-up is needed to fully evaluate the real-world effectiveness of mRNA-1273 overall and in different subgroups of the population over time.

Author contributions

Contributions	Authors
Concept and design	AF, LSS, LQ, KJB, CAT, HFT
Acquisition, analysis, or interpretation of data	AF, LSS, YL, LQ, KJB, BKA, CAT, HFT
Drafting of the manuscript	AF, LSS
Critical revision of the manuscript for important intellectual content	YL, LQ, KJB, BKA, GSL, JHK, JET, YT, CAT, HFT
Statistical analysis	YL, LQ, JET, YT
Obtained funding	CAT, HFT
Administrative, technical, or material support	CAT, GSL, LSS
Supervision	CAT, HFT

Data sharing

Individual-level data reported in this study are not publicly shared. Upon request, and subject to review, KPSC may provide the deidentified aggregate-level data that support the findings of this study. Deidentified data (including participant data as applicable) may be shared upon approval of an analysis proposal and a signed data access agreement

Declaration of interests

AF, LSS, YL, LQ, BKA, GSL, JHK, JET, YT, and HFT are employees of Kaiser Permanente Southern California, which has been contracted by Moderna to conduct this study. KJB is an adjunct investigator at Kaiser Permanente Southern California. CAT is an employee of and a shareholder in Moderna Inc. AF received funding from Pfizer, GlaxoSmithKline, and Gilead unrelated to this manuscript. LSS received funding from GlaxoSmithKline, Dynavax, and Seqirus unrelated to this manuscript. YL received funding from GlaxoSmithKline, Seqirus and Pfizer unrelated to this manuscript. LQ received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript. KJB received funding from GlaxoSmithKline, Dynavax, Pfizer, Gilead, and Seqirus unrelated to this manuscript. BKA received funding from GlaxoSmithKline, Dynavax, Seqirus and Pfizer unrelated to this manuscript. GSL received funding from GlaxoSmithKline unrelated to this manuscript. JHK

received funding from GlaxoSmithKline unrelated to this manuscript. JET received funding from Pfizer unrelated to this manuscript. YT received funding from GlaxoSmithKline unrelated to this manuscript. HFT received funding from GlaxoSmithKline and Seqirus unrelated to this manuscript; HFT also served in advisory boards for Janssen and Pfizer.

Funding

This work was supported by Moderna Inc.

Acknowledgments

This study was funded by Moderna Inc. The authors would like to acknowledge the following Kaiser Permanente Southern California staff: Radha Bathala, Maria Navarro, Elsa Olvera, Brittany Brown, Jeannie Song, and Stephanie Reese Rillon for their contributions in manual chart review; Harpreet Takhar, Michael Aragones, Soon Kyu Choi, Jennifer Charter, Julie Stern, Joy Gelfond, and Lee Childs for their coordination in processing SARS-CoV-2 specimens; and Raul Calderon, Kourtney Kottman, Ana Acevedo, Elmer Ayala, and Jonathan Arguello for their technical and laboratory support in processing SARS-CoV-2 specimens. The authors would like to acknowledge Helix OpCo, LLC, for their whole genome sequencing of SARS-CoV-2 specimens. The authors would also like to acknowledge the contributions by Moderna staff: Yamuna Paila, PhD, and Julie Vanas. Medical writing and editorial assistance were provided by Srividya Ramachandran, PhD, and Jared Mackenzie, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP3) guidelines, funded by Moderna Inc, and under the direction of the authors. The authors thank the patients of Kaiser Permanente for their partnership with us to improve their health. Their information, collected through our electronic health record systems, leads to findings that help us improve care for our members and can be shared with the larger community.

Ethical Approval

The study was reviewed and approved by the KPSC Institutional Review Board (IRB #12758). A waiver of informed consent was obtained as this is an observational study of the authorized and recommended Moderna COVID-19 vaccine administered during routine clinical care. To facilitate the conduct of this study, a waiver was obtained for written HIPAA authorization for research involving use of the EHR.

References

1. Bruxvoort KJ, Sy LS, Qian L, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. *Lancet Reg Health Am* **2021**; 100134.
2. Paris C, Perrin S, Hamonic S, et al. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. *Clin Microbiol Infect* **2021**; 27(11): 1699.e5-.e8.
3. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. *JAMA* **2021**; 326(20):2043-2054.
4. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(20): 753-8.
5. Mallapaty S. COVID vaccines slash viral spread - but Delta is an unknown. *Nature* **2021**; 596(7870): 17-8.
6. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *bioRxiv* **2021**; 2021.01.25.427948.
7. Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(37): 1284-90.
8. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* **2021**; 385(7): 585-94.
9. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis* **2021**; S1473-3099(21)00475-8.
10. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(31): 1059-62.
11. Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. *New England Journal of Medicine* **2021**; 385:1330-1332.
12. Baden LR, El Sahly HM, Essink B, et al. Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge. *medRxiv* **2021**; 2021.09.17.21263624.
13. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. *medRxiv* **2021**; 2021.09.29.21264199.
14. Nasreen S, Chung H, He S, et al. Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. *medRxiv* **2021**; 2021.06.28.21259420.
15. Bajema KL, Dahl RM, Prill MM, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization - Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(37): 1294-9.
16. Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(37): 1291-3.
17. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(38): 1337-43.
18. Scott J, Richterman A, Cevik M. Covid-19 vaccination: evidence of waning immunity is overstated. *BMJ* **2021**; 374: n2320.

19. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. *medRxiv* **2021**: 2021.09.15.21263583.
20. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. *Perm J* **2012**; 16(3): 37-41.
21. California Department of Public Health. Reporting Requirements at a Glance. Available at: <https://eziz.org/assets/docs/COVID19/IMM-1329.pdf>. Accessed 9 December 2021.
22. Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. *J Gerontol A Biol Sci Med Sci* **2018**; 73(7): 980-7.
23. Miettinen OS. *Theoretical Epidemiology: Principles of Occurrence Research in Medicine*: New York: John Wiley & Sons. Print., **1985**.
24. California Department of Public Health. Updated COVID-19 Vaccine Eligibility Guidelines 2021 (updated 12 May 2021). Available at: <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/VaccineAllocationGuidelines.aspx>. Accessed 9 December 2021.
25. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(38): 1337-43.
26. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **2021**; 384(5): 403-16.
27. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. *Clin Infect Dis* **2021**; 73(6): e1376–e9.
28. Malden DE, Bruxvoort KJ, Tseng HF, et al. Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(40): 1415-9.
29. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* **2021**.
30. Centers for Disease Control and Prevention. COVID-19 Vaccine Booster Shots. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html>. Accessed 9 December 2021.

Tables

Table 1. Baseline characteristics of 2-dose mRNA-1273 vaccinated and unvaccinated cohort

	Vaccinated N=927004	Unvaccinated N=927004	Absolute Standardized Difference
	N (%)	N (%)	
Age at index date, years, median (IQR)	52 (37, 65)	51 (36, 65)	0.0452
Age at index date, years			N/A
18-44	339646 (36.6)	339646 (36.6)	
45-64	349556 (37.7)	349556 (37.7)	
65-74	154865 (16.7)	154865 (16.7)	
≥75	82937 (8.9)	82937 (8.9)	
Sex			N/A
Female	505654 (54.5)	505654 (54.5)	
Male	421350 (45.5)	421350 (45.5)	
Race/Ethnicity			N/A
Non-Hispanic White	311799 (33.6)	311799 (33.6)	
Non-Hispanic Black	69159 (7.5)	69159 (7.5)	
Hispanic	357415 (38.6)	357415 (38.6)	
Non-Hispanic Asian	118333 (12.8)	118333 (12.8)	
Other/Unknown	70298 (7.6)	70298 (7.6)	
Body Mass Index ^b			0.0545
<18.5	9848 (1.1)	13021 (1.4)	
18.5 - <25	205813 (22.2)	215470 (23.2)	
25 - <30	269826 (29.1)	272903 (29.4)	
30 - <35	177499 (19.1)	178076 (19.2)	
35 - <40	83982 (9.1)	81874 (8.8)	
40 - <45	36994 (4.0)	32855 (3.5)	
≥45	23525 (2.5)	20579 (2.2)	
Unknown	119517 (12.9)	112226 (12.1)	

Smoking ^b				0.0361
No	667670 (72.0)		663128 (71.5)	
Yes	162747 (17.6)		173785 (18.7)	
Unknown	96587 (10.4)		90091 (9.7)	
Charlson comorbidity score ^a				0.0827
0	646513 (69.7)		681024 (73.5)	
1	130475 (14.1)		115147 (12.4)	
≥2	150016 (16.2)		130833 (14.1)	
Frailty index ^a				0.0456
Quartile 1	191548 (20.7)		187533 (20.2)	
Quartile 2	266325 (28.7)		281684 (30.4)	
Quartile 3	230017 (24.8)		233376 (25.2)	
Quartile 4	239114 (25.8)		224411 (24.2)	
Chronic diseases ^a				
Kidney disease	51638 (5.6)		45129 (4.9)	0.0316
Heart disease	27855 (3.0)		27594 (3.0)	0.0017
Lung disease	71550 (7.7)		65003 (7.0)	0.0270
Liver disease	26146 (2.8)		23954 (2.6)	0.0146
Diabetes	139390 (15.0)		116794 (12.6)	0.0707
Immunocompromised	29784 (3.2)		24102 (2.6)	0.0365
HIV/AIDS	3930 (0.4)		2074 (0.2)	
Leukemia, lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia	10823 (1.2)		9318 (1.0)	
Organ transplant	2750 (0.3)		1910 (0.2)	
Immunosuppressant medications	17467 (1.9)		14539 (1.6)	
Autoimmune conditions ^a	25882 (2.8)		22327 (2.4)	0.0241
Rheumatoid arthritis	11764 (1.3)		10185 (1.1)	
Inflammatory bowel disease	4384 (0.5)		3694 (0.4)	
Psoriasis and psoriatic arthritis	8755 (0.9)		7500 (0.8)	
Multiple sclerosis	1566 (0.2)		1429 (0.2)	

Systemic lupus erythematosus	2124 (0.2)	1772 (0.2)	
Pregnant at index date	5063 (0.5)	10551 (1.1)	0.0648
1st trimester	1609 (0.2)	2625 (0.3)	
2nd trimester	1863 (0.2)	3988 (0.4)	
3rd trimester	1591 (0.2)	3938 (0.4)	
History of SARS-CoV-2 infection ^c	92461 (10.0)	113396 (12.2)	0.0719
History of SARS-CoV-2 molecular test ^c	364575 (39.3)	337279 (36.4)	0.0607
Number of outpatient and virtual visits ^{a,d}			0.2504
0	68573 (7.4)	128820 (13.9)	
1-4	327996 (35.4)	357042 (38.5)	
5-10	263631 (28.4)	231974 (25.0)	
≥11	266804 (28.8)	209168 (22.6)	
Number of emergency department visits ^{a,d}			0.0564
0	806834 (87.0)	789726 (85.2)	
1	88007 (9.5)	97545 (10.5)	
≥2	32163 (3.5)	39733 (4.3)	
Number of hospitalizations ^{a,d}			0.0449
0	887170 (95.7)	878587 (94.8)	
1	32205 (3.5)	38153 (4.1)	
≥2	7629 (0.8)	10264 (1.1)	
Preventive care ^a	691389 (74.6)	568154 (61.3)	0.2878
Medicaid	59896 (6.5)	77950 (8.4)	0.0743
Neighborhood median household income			0.0750
< \$40,000	42362 (4.6)	47664 (5.1)	
\$40,000-\$59,999	182542 (19.7)	194304 (21.0)	
\$60,000-\$79,999	225417 (24.3)	235308 (25.4)	
\$80,000+	476050 (51.4)	447572 (48.3)	
Unknown	633 (0.1)	2156 (0.2)	
KPSC physician/employee	31111 (3.4)	15132 (1.6)	0.1107
Concomitant vaccination ^e	559 (0.1)	N/A	N/A

Time between first and second doses, days, median (IQR)	28 (28-29)	N/A	N/A
Index date			N/A
January 2021	20561 (2.2)	20561 (2.2)	
February 2021	156278 (16.9)	156278 (16.9)	
March 2021	174115 (18.8)	174115 (18.8)	
April 2021	320109 (34.5)	320109 (34.5)	
May 2021	196973 (21.2)	196973 (21.2)	
June 2021	58968 (6.4)	58968 (6.4)	

^a Defined in the one year prior to index date

^b Defined in the two years prior to index date

^c Defined based on all available medical records from March 1, 2020 to index date

^d Indicator of overall health care utilization / care-seeking

^e Among subjects with concomitant vaccines: influenza vaccine (24.0%), Tdap (49.4%), shingles vaccine (4.5%), PCV13/PPSV23 (9.3%), HPV vaccine (8.1%) and other vaccine (9.3%); 32.7% concomitant with 1st dose and 68.7% concomitant with 2nd dose.

Medical center area not shown. The absolute standardized difference of the distribution of the vaccinated and unvaccinated individuals across the 19 medical center areas is 0.2095.

N = sample size; IQR = interquartile range; N/A = not applicable (matching variable or pertains only to vaccinated individuals)

Table 2. Incidence rates, hazard ratios, and vaccine effectiveness of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death

Outcomes	Vaccinated (N=927004)		Unvaccinated (N=927004)		Hazard Ratio (95% CI)		VE % (95% CI)	
	Number of cases	Incidence per 1000 person-years (95% CI)	Number of cases	Incidence per 1000 person-years (95% CI)	Unadjusted	Adjusted ^a	Unadjusted	Adjusted ^a
SARS-CoV-2 infection	7685	19.09 (18.67-19.52)	16809	94.02 (92.61-95.45)	0.17 (0.16-0.17)	0.17 (0.17-0.18)	83.4 (82.9 -83.9)	82.8 (82.2-83.3)
COVID-19 hospitalization	244	0.60 (0.53-0.69)	2361	13.07 (12.55-13.61)	0.04 (0.03-0.04)	0.04 (0.03-0.05)	96.4 (95.9-96.8)	96.1 (95.5-96.6)
COVID-19 hospital death	13	0.03 (0.02-0.06)	163	0.90 (0.77-1.05)	0.03 (0.02-0.05)	0.03 (0.02-0.05)	96.9 (94.5-98.2)	97.2 (94.8-98.4)

^a Adjusted for covariates age groups (4 categories), sex, race/ethnicity, index date (in months), number of outpatient and virtual visits, preventive care, KPSC physician/employee status, medical center area.

N = sample size; CI = confidence interval; VE = vaccine effectiveness

Table 3. Incidence rate, hazard ratio, and vaccine effectiveness of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection by age, sex, race/ethnicity, and Delta period subgroups

	Vaccinated (N=927004)		Unvaccinated (N=927004)		Hazard Ratio (95% CI)		VE % (95% CI)	
	Number of cases	Incidence per 1000 person-years (95% CI)	Number of cases	Incidence per 1000 person-years (95% CI)	Unadjusted	Adjusted ^a	Unadjusted	Adjusted ^a
Age at index date, years								
18-44	3196	23.05 (22.26-23.86)	7145	109.90 (107.38-112.48)	0.16 (0.15-0.17)	0.17 (0.17-0.18)	84.0 (83.3 -84.7)	82.6 (81.7 -83.5)
45-64	2811	19.15 (18.46-19.88)	6912	104.79 (102.35-107.29)	0.14 (0.13-0.15)	0.15 (0.15-0.16)	85.9 (85.2 -86.5)	84.6 (83.8 -85.4)
65-74	1098	14.64 (13.80-15.53)	1877	62.57 (59.81-65.47)	0.19 (0.18-0.21)	0.18 (0.17-0.20)	80.8 (79.3 -82.2)	81.6 (79.9 -83.1)
≥75	580	13.78 (12.71-14.95)	875	49.13 (45.98-52.49)	0.24 (0.22-0.27)	0.22 (0.20-0.25)	75.9 (73.2 -78.3)	77.9 (75.1 -80.3)
Sex								
Female	4459	19.97 (19.39-20.56)	9116	96.18 (94.23-98.18)	0.17 (0.16-0.17)	0.18 (0.17-0.18)	83.2 (82.6 -83.8)	82.4 (81.7 -83.1)
Male	3226	18.00 (17.39-18.64)	7693	91.58 (89.56-93.65)	0.16 (0.16-0.17)	0.17 (0.16-0.18)	83.7 (83.0 -84.4)	83.1 (82.3 -83.9)
Race/Ethnicity								
Non-Hispanic White	2601	18.88 (18.16-19.62)	6061	94.48 (92.13-96.89)	0.17 (0.16-0.18)	0.18 (0.17-0.19)	83.2 (82.4 -84.0)	82.1 (81.1 -83.0)
Non-Hispanic Black	523	17.41 (15.98-18.97)	1497	109.90 (104.47-115.61)	0.14 (0.12-0.15)	0.13 (0.12-0.15)	86.2 (84.7 -87.5)	87.0 (85.5 -88.4)
Hispanic	3488	23.03 (22.28-23.81)	7177	103.15 (100.79-105.57)	0.18 (0.17-0.19)	0.18 (0.17-0.19)	82.1 (81.3 -82.9)	81.8(80.9 -82.6)
Non-Hispanic Asian	612	11.37 (10.50-12.31)	940	52.47 (49.22-55.93)	0.16 (0.14-0.18)	0.17 (0.15-0.19)	83.9 (82.1 -85.6)	83.4 (81.2 -85.4)
Delta period ^b	319	20.38 (18.27-22.75)	1973	146.73 (140.40-153.35)	0.14 (0.12-0.15)	0.13 (0.12-0.15)	86.3 (84.6 -87.9)	86.5 (84.8 -88.0)

^a Adjusted for covariates age groups (in 4 categories, and not adjusted in the age subcohort analysis), sex (not adjusted in the sex subcohort analysis), race/ethnicity (not adjusted in the race/ethnicity subcohort analysis), index date (in months), number of outpatient and virtual visits, preventive care, KPSC physician/employee status, medical center area.

^b Individuals with index dates in June 2021 were followed up to September 30, 2021

N = sample size; CI = confidence interval; VE = vaccine effectiveness


Figure Legend

Figure 1: Flow chart for 2-dose mRNA-1273 analysis cohort


Figure 2. Cumulative incidence estimates by vaccination status in 2-dose mRNA-1273 cohort

- a. SARS-CoV-2 infection
- b. COVID-19 hospitalization
- c. COVID-19 hospital death

Figure 3. Vaccine effectiveness of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection and COVID-19 hospitalization by months after vaccination



A. SARS-CoV-2 infection




Vaccinated

Number at Risk	927004	920182	913569	893694	781528	503249	277279	80351	35
Cumulative Events	0	287	753	2024	3794	5674	6970	7607	7685
Cumulative Incidence	0	0.03	0.08	0.22	0.43	0.72	1.07	1.4	1.62

Unvaccinated

Number at Risk	927004	517337	448848	393262	282996	101643	28552	660	0
Cumulative Events	0	1529	4171	9420	14148	16260	16719	16803	16809
Cumulative Incidence	0	0.24	0.8	2.02	3.34	4.34	5.16	5.76	5.76

B. COVID-19 hospitalization




Vaccinated

Number at Risk	927004	920453	914288	895584	784532	506063	279433	81353	35
Cumulative Events	0	13	28	49	93	171	223	242	244
Cumulative Incidence	0.000	0.001	0.003	0.005	0.011	0.022	0.036	0.045	0.048

Unvaccinated

Number at Risk	927004	518477	452071	400333	290596	104164	29047	678	0
Cumulative Events	0	158	458	1101	1780	2184	2334	2361	2361
Cumulative Incidence	0.000	0.026	0.089	0.239	0.430	0.624	0.901	1.130	1.130

C. COVID-19 hospital death



Vaccinated

Number at Risk	927004	920465	914313	895626	784606	506169	279528	81363	35
Cumulative Events	0	1	2	4	10	12	13	13	13
Cumulative Incidence	0.000	0.000	0.000	0.000	0.001	0.001	0.002	0.002	0.002

Unvaccinated

Number at Risk	927004	518612	452462	401237	291754	104725	29272	678	0
Cumulative Events	0	15	38	74	119	156	163	163	163
Cumulative Incidence	0.000	0.003	0.007	0.016	0.028	0.048	0.058	0.058	0.058

Vaccine Effectiveness (95% CI), %

